John Pulice

Excited to share the final published version of my PhD work out today in @MolecularCell! See below for a thread of updates for the final version from the preprint! 1/ cell.com/molecular-cell…

@3rdMoment @Sturgeons_Law All PhD programs at Harvard are through FAS

@Sturgeons_Law Where does it say they are not cutting business PhD programs? This article is about what FAS is doing, not what HBS is doing or not doing.

They're cutting STEM PhDs who do actual research but not their worthless Business PhD programs.

Nice new preprint on oncogene alterations in lung adenocarcinoma that reinforces what we and others have seen with mEGFR and NKX2-1! biorxiv.org/content/10.110…

Very curious to see how much of an outlier NKX2-1 is as more TFs and studies interrogate TF dosage in a mechanistic fashion!

ICYMI: since the preprint, we added extensive interrogation of NKX2-1 dosage to the final manuscript by both titrated lentiviral overexpression and knockdown, with distinct effects of dosage in the two contexts (OE: linear/thresholded, KD: mostly linear). cell.com/molecular-cell…

Cool new paper from the @WJGreenleaf lab on TF dosage by ATAC-seq! biorxiv.org/content/10.110…

And if you're interested, check out our study on how NKX2-1 functions as a pioneer-like factor to drive lineage addiction through enhancer remodeling in lung adenocarcinoma! cell.com/molecular-cell…

It's a big week for NKX2-1! Check out new studies on (1) how HNF4a modulates NKX2-1-mediated lineage specification (genesdev.cshlp.org/content/early/…) and (2) how NKX2-1 drives neuroendocrine differentiation in prostate cancer (nature.com/articles/s4158…)

@jaybradner @Amgen Interesting to see the role of NKX2-1/TTF-1 here, we saw a role for it in EGFR persistence and speculated it might have a role for KRAS too! Would be curious if NKX2-1 amplification status has any role here or if it’s just lineage state cell.com/molecular-cell…

A new Nature Medicine study sheds light on why KRAS G12C–mutated NSCLC patients respond differently to treatment. Insights from two trials reveal molecular features and early blood-based markers that may predict outcomes. Grateful to our @Amgen team involved. #MyCompany nature.com/articles/s4159…

Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma dlvr.it/TK0w6T

@Berkley_Gryder Thanks Berkley! Hope all is well!!

Wonderful paper! "Focal amplification targets a lineage super-enhancer" @JohnPulice is a star on the rise, check it out!

Online Now: Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma dlvr.it/TJlXG5

@MolecularCell We've endeavored to make all the reagents and methods in this article as transparent and reproducible as possible. We deposited all plasmids (inc. pDONR cloning backbones and dTag OE destination vectors) on Addgene for easy use addgene.org/browse/article… 15/

@MolecularCell NKX2-1 is a complicated gene in cancer, with conflicting data for its role as a tumor suppressor and oncogene. Our data suggest NKX2-1 is a common oncogene and rare tumor suppressor in human LUAD, with it's TS role restricted to the rare IMA subtype 14/ cell.com/cancer-cell/fu…

Excited to share the final published version of my PhD work out today in @MolecularCell! See below for a thread of updates for the final version from the preprint! 1/ cell.com/molecular-cell…